Afstyla (Antihemophilic factor [recombinant], single chain) for Hemophilia

Overview
Afstyla is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in children and adults with factor VIII deficiency due to hemophilia A. Afstyla can also be used for perioperative (before, during, and after surgery) care and for routine prophylaxis. The technical name of Afstyla is Antihemophilic factor (recombinant), single chain.

Afstyla is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.

How do I take it?
Prescribing information states that Afstyla is given as an intravenous injection.

Afstyla comes in single-use vials as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for Afstyla lists common side effects including dizziness and hypersensitivity.

Rare but serious side effects listed for Afstyla include life-threatening hypersensitivity reactions and the development of inhibitors.

For more details about this treatment, visit:

Afstyla – CSL Behring
http://www.afstyla.com/